NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

So why has NWBO not reported results on the other cohorts of the trial?

Background: The trial had some additional cohorts outside of the main 233 that were to be analyzed. The most significant group was 80 patients who failed the MRI after radiation and were randomized into their own little trial. They would have no cross-over and OS would be the primary endpoint. In short, a valid, if small, randomized OS trial.

And NWBO buried that data, Why? Even at N=80 I would expect it to be stat sig if the curves looked like the ECA comp. That would be hugely positive news, Even I would say that would make the chance of approval significantly better.

And yet, crickets.